No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
EBS250117C19000
- 0.05
- 0.000.00%
15min DelayClose Jan 13 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume6 Open Interest19.00Strike Price0.00Turnover381.45%IV102.44%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0408Delta0.0255Gamma188.20Leverage Ratio-0.0351Theta0.0000Rho7.68Eff Leverage0.0008Vega
Intraday
- 5D
- Daily
News
Express News | Emergent BioSolutions Gains Exclusive Commercial Rights to Kloxxado® (Naloxone Hci) Nasal Spray From Hikma Pharmaceuticals
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO (Naloxone HCI) Nasal Spray From Hikma Pharmaceuticals
Emergent BioSolutions Receives $16.7M Contract Option To Continue Development Collaboration With BARDA On Ebanga Treatment For Ebola
Express News | Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration With Barda on Ebanga™ (Ansuvimab-Zykl) Treatment for Ebola
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration With BARDA on Ebanga (Ansuvimab-zykl) Treatment for Ebola
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $15